vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Core Insights - vTv Therapeutics has appointed a distinguished Scientific Advisory Board (SAB) to guide the clinical development of cadisegliatin for type 1 diabetes, which is currently in Phase 3 trials [1][2][4] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin as its lead candidate [7] Scientific Advisory Board - The SAB includes experts in endocrinology and diabetes research, such as Dr. John Buse, Dr. Alfonso Galderisi, Dr. Mark Evans, Dr. Chantal Mathieu, Dr. Alexander Fleming, and Dr. Klara Klein, who will provide strategic guidance on clinical trial planning and regulatory strategy [2][8] Cadisegliatin Details - Cadisegliatin (TTP399) is a novel oral small molecule that acts as a liver-selective glucokinase activator, being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes [5][6]